key: cord-0987259-jzpwo5un
authors: Matushek, Scott M.; Beavis, Kathleen G.; Abeleda, Ana; Bethel, Cindy; Hunt, Carlissa; Gillen, Stephanie; Moran, Angelica; Tesic, Vera
title: Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies
date: 2020-05-13
journal: bioRxiv
DOI: 10.1101/2020.05.11.089862
sha: 6079d6c97535ad63348b6cbb4e33b2efc80a06ae
doc_id: 987259
cord_uid: jzpwo5un

As the Coronavirus 2019 (COVID-19) pandemic evolves, the development of immunoassays to help determine exposure and potentially predict immunity has become a pressing priority. In this report we present the performance of the EUROIMMUN enzyme-linked immunosorbent assay (ELISA) for semi-quantitative detection of IgA and IgG antibodies in serum and plasma samples using recombinant S1 domain of the SARS-CoV-2 spike protein as antigen. Specimens from patients, with and without COVID-19 infection, were tested at the University of Chicago Clinical Microbiology and Immunology Laboratory. Of 57 samples from COVID-19 PCR-negative patients, including 28 samples positive for common human coronavirus strains, 53 tested negative and 4 tested positive for IgA (93.0% agreement) while 56 tested negative and 1 tested positive for IgG (98.2% agreement). For COVID-19 PCR-positive patients, 29 of 30 (96.7%) samples collected ≥3 days after positive PCR were positive for IgA, and 28 of 28 samples collected ≥4 days after positive PCR were positive for IgG. The EUROIMMUN Anti-SARS-CoV-2 ELISA Assay demonstrates excellent sensitivity for detection of IgA and IgG antibodies from samples collected ≥3 days and ≥4 days, respectively, after COVID-19 diagnosis by PCR. This assay did not demonstrate cross reaction in any of the 28 samples from patients with common human coronaviruses, including types HKU1, NL63, CV229E, and OC43.

The EUROIMMUN Anti-SARS-CoV-2 ELISA Assay demonstrates excellent sensitivity 32 for detection of IgA and IgG antibodies from samples collected ≥3 days and ≥4 days, 33 respectively, after COVID-19 diagnosis by PCR. This assay did not demonstrate cross 34 

Chronological 182 evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-183 associated coronavirus

Evaluation of nine commercial SARS-CoV-2

Lamer 192 MM

Severe acute respiratory syndrome 195

coronavirus 2−specific antibody responses in coronavirus disease 2019 patients

A total of 28 unique samples that tested positive by BioFire FilmArray RP2 panel for 140 common human coronaviruses including types 229E, NL63, HKU1 and OC43 were 141 tested for cross reactivity. All 28 tested negative for both IgA and IgG antibodies.